Ciliary neurotrophic factor
- Generic Name
- Ciliary neurotrophic factor
- Drug Type
- Biotech
- CAS Number
- 133423-39-9
- Unique Ingredient Identifier
- CR102F038W
- Background
NT-501 is an intraocular implant that contains human cells that have been genetically modified to secrete ciliary neurotrophic factor (CNTF). It is under investigation for the treatment of retinitis pigmentosa and age-related macular degeneration.
- Indication
Investigated for use/treatment in eye disorders/infections, macular degeneration, and retinal disorders (unspecified).
Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma
- First Posted Date
- 2020-10-06
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 30
- Registration Number
- NCT04577300
- Locations
- ๐บ๐ธ
Byers Eye Institute at Stanford University, Palo Alto, California, United States
Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 54
- Registration Number
- NCT02862938
- Locations
- ๐บ๐ธ
Byers Eye Institute at Stanford University, Palo Alto, California, United States
Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa
- Conditions
- Retinitis PigmentosaUsher Syndrome Type 2Usher Syndrome Type 3
- Interventions
- Procedure: Sham
- First Posted Date
- 2012-02-10
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- Neurotech Pharmaceuticals
- Target Recruit Count
- 22
- Registration Number
- NCT01530659
- Locations
- ๐บ๐ธ
University of California, San Francisco, San Francisco, California, United States
NT-501 CNTF Implant for Ischemic Optic Neuropathy: Safety, Neuroprotection and Neuroenhancement
- Conditions
- Ischemic Optic Neuropathy/Optic Nerve Stroke
- Interventions
- First Posted Date
- 2011-08-08
- Last Posted Date
- 2016-08-02
- Lead Sponsor
- Jeffrey L Goldberg
- Target Recruit Count
- 11
- Registration Number
- NCT01411657
- Locations
- ๐บ๐ธ
Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, United States
NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and Neuroenhancement
- First Posted Date
- 2011-08-03
- Last Posted Date
- 2016-08-02
- Lead Sponsor
- Jeffrey L Goldberg
- Target Recruit Count
- 11
- Registration Number
- NCT01408472
- Locations
- ๐บ๐ธ
Bascom Palmer Eye Institute, University of Miami, Miami, Florida, United States
A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa
- First Posted Date
- 2007-03-15
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Neurotech Pharmaceuticals
- Target Recruit Count
- 73
- Registration Number
- NCT00447980
- Locations
- ๐บ๐ธ
The Hamilton Eye Institute, Memphis, Tennessee, United States
๐บ๐ธRetina Foundation of Southwest, Dallas, Texas, United States
๐บ๐ธThe University of Utah - John A. Moran Eye Center, Salt Lake City, Utah, United States
A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration
- Conditions
- Nonexudative Age-Related Macular Degeneration, Unspecified Eye, Intermediate Dry Stage
- Interventions
- Other: Sham Procedure
- First Posted Date
- 2007-03-15
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Neurotech Pharmaceuticals
- Target Recruit Count
- 53
- Registration Number
- NCT00447954
- Locations
- ๐บ๐ธ
Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
๐บ๐ธBascom Palmer Eye Institute, Miami, Florida, United States
๐บ๐ธBeaumont Eye Institute, Royal Oaks, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.